Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 6/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.74 |
| ▸ | HIF1A | Q16665 | 6/20 | 0.74 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.74 |
| ▸ | SLC7A5 | Q01650 | 5/20 | 0.74 |
| ▸ | RECQL | P46063 | 4/20 | 0.74 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.74 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.74 |
| ▸ | USP2 | O75604 | 2/20 | 0.74 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.74 |
| ▸ | HTR2A | P28223 | 2/20 | 0.74 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.74 |
| ▸ | EGFR | P00533 | 2/20 | 0.74 |
| ▸ | LCK | P06239 | 1/20 | 0.74 |
| ▸ | FYN | P06241 | 1/20 | 0.74 |
| ▸ | KDM6B | O15054 | 1/20 | 0.56 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.55 |
| ▸ | ALOX12 | P18054 | 4/20 | 0.53 |
| ▸ | HPGD | P15428 | 4/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21729924 | 1.00 | ALOX15 (0.74) | ALOX15KDM4EHIF1AHSD17B10SLC7A5 | |
| SCHEMBL13661903 | 1.00 | ALOX15 (0.74) | ALOX15KDM4EHIF1AHSD17B10SLC7A5 | |
| SCHEMBL20765409 | 1.00 | ALOX15 (0.74) | ALOX15KDM4EHIF1AHSD17B10SLC7A5 | |
| Hydrochloric Acid SCHEMBL20765475 | 0.98 | ALOX15 (0.72) | ALOX15KDM4EHIF1AHSD17B10SLC7A5 | |
| Hydrochloric Acid SCHEMBL20764445 | 0.98 | ALOX15 (0.72) | ALOX15KDM4EHIF1AHSD17B10SLC7A5 | |
| Levodopa SCHEMBL27853956 | 0.86 | SLC7A5 (0.93) | ALOX15KDM4EHIF1AHSD17B10SLC7A5 | |
| Levodopa SCHEMBL30777603 | 0.86 | SLC7A5 (0.93) | ALOX15KDM4EHIF1AHSD17B10SLC7A5 | |
| Levodopa SCHEMBL11000382 | 0.85 | SLC7A5 (1.00) | ALOX15KDM4EHIF1AHSD17B10SLC7A5 | |
| Levodopa SCHEMBL116907 | 0.85 | SLC7A5 (1.00) | ALOX15KDM4EHIF1AHSD17B10SLC7A5 | |
| Levodopa SCHEMBL704089 | 0.85 | SLC7A5 (1.00) | ALOX15KDM4EHIF1AHSD17B10SLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3380076-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING LEVODOPA AMIDE AND USES THEREOF | Neuroderm, Ltd. (IL) | 2018-10-03 | — | — | EP | claimed |
| CN-103857440-B | Antimycotic and antibacterium prodrug based on conjugate | 维奥姆生物科学有限公司 | 2018-09-25 | — | — | CN | claimed |
| CN-108495617-A | Including the pharmaceutical composition of levodopa amide and its purposes | 纽罗德姆有限公司 | 2018-09-04 | — | — | CN | claimed |
| CN-108218744-A | A kind of coffee DOPA amide carbamate compound, preparation method and application | 南阳师范学院 | 2018-06-29 | — | — | CN | claimed |
| US-20170296491-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING LEVODOPA AMIDE AND USES THEREOF | NEURODERM, LTD. (IL) | 2017-10-19 | — | — | US | claimed |
| WO-2017090039-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING LEVODOPA AMIDE AND USES THEREOF | NEURODERM LTD. (IL) | 2017-06-01 | — | — | WO | claimed |
| CN-106232110-A | Ion channel activation agent and using method | 弗莱克斯制药股份有限公司 | 2016-12-14 | — | — | CN | claimed |
| CN-103857440-A | Conjugate-based antifungal and antibacterial prodrugs | VYOME BIOSCIENCES | 2014-06-11 | — | — | CN | claimed |
| US-8048926-B2 | L-DOPA amide derivatives and uses thereof | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2011-11-01 | — | — | US | claimed |
| EP-1596808-A4 | L-DOPA AMIDE DERIVATIVES AND USES THEREOF | YISSUM RES DEV CO (IL) | 2007-04-04 | — | — | EP | claimed |
| US-20060025385-A1 | L-DOPA amide derivatives and uses thereof | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2006-02-02 | — | — | US | claimed |
| EP-1596808-A2 | L-DOPA AMIDE DERIVATIVES AND USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2005-11-23 | — | — | EP | claimed |
| WO-2004069146-A2 | L-DOPA AMIDE DERIVATIVES AND USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2004-08-19 | — | — | WO | claimed |
| US-11969401-B2 | Compositions and methods for treating or limiting development of age-related macular degeneration | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2024-04-30 | — | — | US | disclosed |
| US-20220023245-A1 | COMPOSITIONS AND METHODS FOR TREATING OR LIMITING DEVELOPMENT OF AGE-RELATED MACULAR DEGENERATION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-01-27 | — | — | US | disclosed |
| US-20220016253-A1 | L-DOPA AND/OR DOPA DECARBOXYLSE INHIBITORS CONJUGATED TO SUGAR FOR THE TREATMENT OF DOPAMINE-RESPONSIVE DISORDERS | B. G. NEGEV TECHNOLOGIES AND APPLICATIONS LTD., AT BEN-GURION UNIVERSITY (IL) | 2022-01-20 | — | — | US | disclosed |
| WO-2004069146-A2 | L-DOPA AMIDE DERIVATIVES AND USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2004-08-19 | — | — | WO | disclosed |
| US-5298144-A | Chemically wired fructose dehydrogenase electrodes | THE YELLOW SPRINGS INSTRUMENT COMPANY, INC. (US) | 1994-03-29 | — | — | US | disclosed |
| EP-0278647-A3 | ELECTRONCHEMICAL PROCESSES INVOLVING ENZYMES | AT&T Corp. (US) | 1989-09-20 | — | — | EP | disclosed |
| EP-0278647-A2 | Electronchemical processes involving enzymes | AT&T Corp. (US) | 1988-08-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220023245-A1 | COMPOSITIONS AND METHODS FOR TREATING OR LIMITING DEVELOPMENT OF AGE-RELATED MACULAR DEGENERATION | MTNR1A, MC1R, MTNR1B | ALOX15 674/4885KDM4E 3969/4885HIF1A 1469/4885 |
| US-11969401-B2 | Compositions and methods for treating or limiting development of age-related macular degeneration | MTNR1A, MC1R, MTNR1B | ALOX15 674/4885KDM4E 3969/4885HIF1A 1469/4885 |
| US-20170296491-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING LEVODOPA AMIDE AND USES THEREOF | PARK7, SNCA, LRRK2 | ALOX15 783/4885KDM4E 1717/4885HIF1A 4563/4885 |
| US-20060025385-A1 | L-DOPA amide derivatives and uses thereof | SNCA, DBH, PARK7 | ALOX15 1467/4885KDM4E 3395/4885HIF1A 3278/4885 |
| US-20220016253-A1 | L-DOPA AND/OR DOPA DECARBOXYLSE INHIBITORS CONJUGATED TO SUGAR FOR THE TREATMENT OF DOPAMINE-RESPONSIVE DISORDERS | COMT, SLC6A3, DDT | ALOX15 1724/4885KDM4E 1999/4885HIF1A 2614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.